Elite Journal of Immunology. Volume 2 issue 3(2024), Pp. 62-79
https://epjournals.com/journals/EJI

Immunodeficiency and Immune Reconstitution in Pediatric HIV: Mechanisms, Challenges, and Therapeutic Strategies

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda

[2]School of Nursing Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Pediatric HIV infection poses unique challenges to the developing immune system, leading to profound immunodeficiency and impaired immune reconstitution despite antiretroviral therapy (ART). This review examines the mechanisms underlying immunodeficiency and immune reconstitution in pediatric HIV, focusing on the interplay between viral pathogenesis, host immune responses, and developmental factors. We discuss the clinical manifestations of immunodeficiency in pediatric HIV, including increased susceptibility to opportunistic infections and immune dysregulation. Additionally, we explore the challenges of immune reconstitution in children receiving ART, including incomplete immune recovery, persistent immune activation, and long-term complications. Finally, we review therapeutic strategies aimed at optimizing immune reconstitution and improving outcomes in pediatric HIV, including early initiation of ART, adjunctive therapies, and interventions to prevent opportunistic infections and immune dysregulation.

Keywords*: pediatric HIV, immunodeficiency, immune reconstitution, antiretroviral therapy, opportunistic infections, immune dysregulation*

Citation: Obeagu EI, Obeagu GU. Immunodeficiency and Immune Reconstitution in Pediatric HIV: Mechanisms, Challenges, and Therapeutic Strategies. Elite Journal of Immunology, 2024; 2(3): 62-79

Introduction

Pediatric HIV infection presents unique challenges to the developing immune system, profoundly affecting immune function and leading to increased susceptibility to infections. HIV primarily targets CD4+ T cells, key players in orchestrating the adaptive immune response, resulting in progressive immunodeficiency. Despite advances in antiretroviral therapy (ART), achieving immune reconstitution remains a significant challenge in pediatric HIV care. The intricate interplay between viral pathogenesis, host immune responses, and developmental factors shapes the trajectory of immunodeficiency and immune reconstitution in children with HIV/AIDS. Immunodeficiency in pediatric HIV is characterized by CD4+ T cell depletion, impaired T cell function, and dysregulation of immune signaling pathways. These disruptions compromise the ability of the immune system to mount effective responses against pathogens, leading to increased susceptibility to opportunistic infections. Common opportunistic infections in children with HIV/AIDS include Pneumocystis jirovecii pneumonia, Mycobacterium avium complex, cytomegalovirus, and toxoplasmosis, among others. Furthermore, immune dysregulation in pediatric HIV is associated with complications such as autoimmune disorders, malignancies, and neurocognitive impairment, further impacting morbidity and mortality in affected children.[1-30]

Despite effective viral suppression with ART, immune reconstitution in pediatric HIV remains incomplete and often characterized by persistent immune activation and inflammation. Children receiving ART may exhibit suboptimal CD4+ T cell recovery and impaired T cell function, predisposing them to ongoing immune dysfunction and increased risk of opportunistic infections. Long-term complications of HIV infection and ART toxicity may further hinder immune reconstitution and impact overall health outcomes in affected children. Thus, understanding the mechanisms underlying immunodeficiency and immune reconstitution is essential for optimizing treatment strategies and improving outcomes in pediatric HIV/AIDS. The challenges of immune reconstitution in pediatric HIV call for a comprehensive approach that includes early initiation of ART, adjunctive therapies targeting immune dysregulation, and interventions to prevent opportunistic infections. Early initiation of ART in infants and children diagnosed with HIV infection is crucial for achieving viral suppression and preserving immune function. Adjunctive therapies, such as cytokine therapy and immunomodulatory agents, may enhance immune reconstitution by promoting T cell expansion and proliferation. Furthermore, interventions to prevent opportunistic infections, including antimicrobial prophylaxis and vaccination, are essential for reducing morbidity and mortality in children with HIV/AIDS. By addressing the complexities of immune reconstitution and implementing comprehensive treatment approaches, healthcare providers can improve the long-term health and well-being of pediatric patients living with HIV.[31-60]

Mechanisms of Immunodeficiency in Pediatric HIV

HIV primarily targets CD4+ T cells, which play a central role in orchestrating the adaptive immune response. Upon infection, HIV binds to CD4 receptors on the surface of CD4+ T cells, leading to

viral entry, replication, and eventual cell death. The continuous depletion of CD4+ T cells results in a progressive decline in their numbers, compromising the immune system's ability to mount effective responses against pathogens. Depletion of CD4+ T cells is a hallmark of pediatric HIV infection and a major contributor to immunodeficiency in affected children. In addition to CD4+ T cell depletion, HIV infection also impairs the function of remaining T cells, including CD8+ T cells. CD8+ T cells play a crucial role in viral control and clearance by recognizing and eliminating infected cells. However, in pediatric HIV infection, CD8+ T cells may exhibit functional exhaustion, characterized by reduced cytotoxicity and cytokine production. Impaired T cell function further compromises the immune system's ability to combat infections, contributing to immunodeficiency in affected children. HIV-induced dysregulation of immune signaling pathways contributes to immunodeficiency by disrupting immune cell activation, differentiation, and effector function. Chronic immune activation, characterized by elevated levels of proinflammatory cytokines and chemokines, drives immune dysfunction and contributes to CD4+ T cell depletion and impaired T cell function. Additionally, HIV alters immune checkpoint pathways, such as PD-1/PD-L1 and CTLA-4, which regulate T cell activation and immune homeostasis. Dysregulation of immune checkpoint signaling further exacerbates immunodeficiency by promoting T cell exhaustion and impairing immune responses.[61-83]

HIV infection disrupts the architecture of lymphoid tissues, including lymph nodes, spleen, and gut-associated lymphoid tissue (GALT), which are essential for immune cell development, activation, and surveillance. The destruction of lymphoid tissue architecture leads to a loss of immune cell niches, impaired antigen presentation, and altered cytokine gradients, compromising immune function. Disruption of lymphoid tissue architecture contributes to the systemic immune dysfunction observed in pediatric HIV infection and exacerbates immunodeficiency in affected children. HIV infection also affects B cell function, impairing antibody production and humoral immunity. B cells play a crucial role in antibody-mediated immune responses and are essential for long-term protection against pathogens. However, in pediatric HIV infection, B cell function may be compromised, leading to reduced antibody titers and impaired vaccine responses. Impaired B cell function further exacerbates immunodeficiency and increases susceptibility to infections in affected children.[84-98]

Clinical Manifestations of Immunodeficiency in Pediatric HIV

Pediatric HIV infection is characterized by progressive immunodeficiency, leading to increased susceptibility to opportunistic infections and other complications. The clinical manifestations of immunodeficiency in children with HIV/AIDS vary depending on the degree of immune suppression and the presence of comorbidities. Children with HIV/AIDS are at increased risk of opportunistic infections due to impaired immune function. Opportunistic infections can affect various organ systems and present with a wide range of clinical symptoms. Common opportunistic infections in pediatric HIV include Pneumocystis jirovecii pneumonia (PCP), Mycobacterium avium complex (MAC) infection, cytomegalovirus (CMV) retinitis, cryptococcal meningitis, and disseminated tuberculosis. These infections often manifest with respiratory symptoms,

gastrointestinal symptoms, neurological manifestations, or systemic signs of infection. Children with HIV/AIDS are prone to recurrent bacterial infections, including bacterial pneumonia, sepsis, urinary tract infections, and skin and soft tissue infections. Bacterial infections may be more severe and recurrent in children with advanced immunodeficiency, requiring prompt diagnosis and appropriate antimicrobial therapy. Common pathogens implicated in bacterial infections in pediatric HIV include Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and Salmonella species.[99-120]

Fungal infections are common in children with HIV/AIDS, particularly those with severe immunodeficiency. Candidiasis, including oral thrush and esophageal candidiasis, is a common fungal infection in pediatric HIV. Invasive fungal infections, such as cryptococcal meningitis and disseminated histoplasmosis, can occur in severely immunocompromised children and present with systemic symptoms, including fever, headache, and altered mental status. Children with HIV/AIDS are susceptible to viral infections, including reactivation of latent viruses and primary viral infections. Cytomegalovirus (CMV) infection is a common viral opportunistic infection in pediatric HIV, presenting with retinitis, pneumonitis, or gastrointestinal manifestations. Herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections can cause mucocutaneous lesions and disseminated disease in children with HIV/AIDS. Additionally, children with HIV/AIDS may experience prolonged or severe viral respiratory infections, such as influenza and respiratory syncytial virus (RSV) infections. Immunodeficiency in pediatric HIV can lead to failure to thrive, growth delay, and developmental delays. Chronic infections, malabsorption, and metabolic disturbances contribute to poor growth and nutritional deficiencies in children with HIV/AIDS. Delayed puberty and impaired cognitive development may also occur in children with advanced immunodeficiency, impacting overall health and quality of life.[121-141]

Challenges of Immune Reconstitution in Pediatric HIV

Despite significant advancements in antiretroviral therapy (ART), achieving optimal immune reconstitution remains a significant challenge in pediatric HIV care. Immune reconstitution refers to the restoration of immune function following suppression of viral replication with ART. However, several factors contribute to incomplete immune recovery and persistent immune dysfunction in children with HIV/AIDS, leading to ongoing clinical challenges. One of the primary challenges of immune reconstitution in pediatric HIV is the incomplete recovery of CD4+ T cell counts despite viral suppression with ART. Children may fail to achieve normal CD4+ T cell levels even after years of suppressive therapy, leading to ongoing immunodeficiency and increased susceptibility to opportunistic infections. Factors contributing to incomplete immune recovery include irreversible damage to the thymus, poor adherence to ART, drug resistance, and persistent immune activation. Despite effective viral suppression with ART, children with HIV/AIDS often experience persistent immune activation and inflammation. Chronic immune activation is associated with ongoing viral replication, microbial translocation, and dysregulation of immune signaling pathways. Persistent immune activation contributes to immune exhaustion, T cell

dysfunction, and impaired immune reconstitution, further complicating the management of pediatric HIV.[142-148]

Children with HIV/AIDS may exhibit premature immune senescence, characterized by accelerated aging of the immune system and immune dysfunction. HIV infection accelerates the aging process of the immune system, leading to premature thymic involution, telomere shortening, and loss of immune diversity. Immune senescence impairs immune reconstitution and increases the risk of age-related comorbidities, including cardiovascular disease, metabolic disorders, and neurocognitive impairment. Long-term complications of HIV infection and ART toxicity may impact immune reconstitution and overall health outcomes in children with HIV/AIDS. Chronic exposure to ART medications may cause mitochondrial toxicity, metabolic disturbances, and bone marrow suppression, affecting immune cell function and proliferation. Additionally, children with HIV/AIDS are at increased risk of developing non-AIDS-related comorbidities, such as cardiovascular disease, renal dysfunction, and neurocognitive impairment, which further impact immune reconstitution and quality of life. The persistence of latent HIV reservoirs poses a significant barrier to immune reconstitution and viral eradication in children with HIV/AIDS. Latently infected CD4+ T cells and other cellular reservoirs harbor replication-competent HIV provirus, allowing for viral persistence despite suppressive ART. Strategies to eliminate latent HIV reservoirs, such as latency-reversing agents and immune-based therapies, are under investigation but have yet to be successfully implemented in clinical practice.[149-151]

Therapeutic Strategies for Optimizing Immune Reconstitution

Optimizing immune reconstitution in pediatric HIV infection requires a multifaceted approach that addresses the underlying mechanisms of immune dysfunction and aims to restore immune function and improve clinical outcomes. Early initiation of ART is critical for achieving viral suppression and preserving immune function in children with HIV/AIDS. Initiating ART as soon as possible after diagnosis helps prevent further immune damage, preserves immune cell populations, and reduces the risk of opportunistic infections. Early ART initiation is associated with better immune recovery and long-term clinical outcomes in pediatric HIV. Intensification of ART regimens with additional antiretroviral agents or immune modulators may enhance immune reconstitution in children with HIV/AIDS. Strategies such as adding integrase inhibitors, boosting protease inhibitors, or using novel antiretroviral agents with immune-enhancing properties may improve viral suppression and immune recovery. Intensification of ART may be considered in children with suboptimal immune responses or persistent immune activation despite suppressive therapy. Adjunctive therapies aimed at modulating immune responses and reducing immune activation may complement ART in optimizing immune reconstitution in pediatric HIV. Immunomodulatory agents, such as interleukin-2 (IL-2) and interleukin-7 (IL-7), have been investigated as adjunctive therapies to promote T cell expansion and proliferation. Additionally, therapies targeting immune checkpoints, such as anti-PD-1 antibodies, may enhance immune function and improve immune reconstitution in children with HIV/AIDS.[152-157]

Citation: Obeagu EI, Obeagu GU. Immunodeficiency and Immune Reconstitution in Pediatric HIV: Mechanisms, Challenges, and Therapeutic Strategies. Elite Journal of Immunology, 2024; 2(3): 62-79

Prompt diagnosis and treatment of opportunistic infections are essential for preventing immune damage and promoting immune reconstitution in children with HIV/AIDS. Antimicrobial prophylaxis against opportunistic infections, such as Pneumocystis jirovecii pneumonia and Mycobacterium avium complex, helps prevent recurrent infections and preserves immune function. Additionally, early initiation of treatment for opportunistic infections, along with supportive care measures, helps mitigate immune activation and inflammation. Immunization and vaccination play a crucial role in optimizing immune reconstitution and preventing infectious complications in children with HIV/AIDS. Children living with HIV should receive age-appropriate vaccinations according to national guidelines, including vaccinations against bacterial, viral, and fungal pathogens. Immunization against influenza, pneumococcus, hepatitis B, and human papillomavirus (HPV) is particularly important for children with HIV/AIDS to reduce the risk of vaccine-preventable diseases and enhance immune responses. Adequate nutrition and wellness interventions are essential for supporting immune reconstitution and overall health in children with HIV/AIDS. Nutritional support, including micronutrient supplementation and growth monitoring, helps address malnutrition and promote optimal immune function. Wellness interventions, such as psychosocial support, mental health services, and adherence counseling, are also important for promoting resilience and well-being in children living with HIV/AIDS.[140-150]

Conclusion

Optimizing immune reconstitution in pediatric HIV infection remains a significant clinical challenge, despite advancements in antiretroviral therapy (ART) and supportive care. Immune reconstitution is essential for achieving long-term viral suppression, preventing opportunistic infections, and improving overall health outcomes in children living with HIV/AIDS. However, several factors contribute to incomplete immune recovery and persistent immune dysfunction in this population. Therapeutic strategies aimed at optimizing immune reconstitution include cytokine therapy, immunomodulatory agents, and interventions to enhance immune function and reduce chronic inflammation. Additionally, early diagnosis and treatment of opportunistic infections, nutritional support, and psychosocial interventions are essential components of comprehensive management for children with HIV/AIDS.

References

1. Torow N, Hand TW, Hornef MW. Programmed and environmental determinants driving neonatal mucosal immune development. Immunity. 2023;56(3):485-499.
2. Tourneur E, Chassin C. Neonatal immune adaptation of the gut and its role during infections. Journal of Immunology Research. 2013.
3. Socha-Banasiak A, Pawłowska M, Czkwianianc E, Pierzynowska K. From intrauterine to extrauterine Life—The role of endogenous and exogenous factors in the regulation of the intestinal microbiota community and gut maturation in early life. Frontiers in nutrition. 2021; 8:696966.
4. Kan B, Razzaghian HR, Lavoie PM. An immunological perspective on neonatal sepsis. Trends in molecular medicine. 2016;22(4):290-302.

Citation: Obeagu EI, Obeagu GU. Immunodeficiency and Immune Reconstitution in Pediatric HIV: Mechanisms, Challenges, and Therapeutic Strategies. Elite Journal of Immunology, 2024; 2(3): 62-79

5. Henneke P, Kierdorf K, Hall LJ, Sperandio M, Hornef M. Perinatal development of innate immune topology. Elife. 2021;10: e67793.
6. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
7. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
8. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
9. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
10. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
11. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001
12. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
13. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
14. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
15. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
16. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.

Citation: Obeagu EI, Obeagu GU. Immunodeficiency and Immune Reconstitution in Pediatric HIV: Mechanisms, Challenges, and Therapeutic Strategies. Elite Journal of Immunology, 2024; 2(3): 62-79

17. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
18. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
19. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
20. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
21. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
22. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.
23. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
24. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
25. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in

Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005

26. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
27. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
28. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
29. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
30. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
31. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
32. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
33. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
34. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf

Citation: Obeagu EI, Obeagu GU. Immunodeficiency and Immune Reconstitution in Pediatric HIV: Mechanisms, Challenges, and Therapeutic Strategies. Elite Journal of Immunology, 2024; 2(3): 62-79

35. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
36. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
37. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science. 2024;2(3):59-72.
38. Muenchhoff M, Prendergast AJ, Goulder PJ. Immunity to HIV in early life. Frontiers in immunology. 2014; 5:391.
39. Dalzini A, Petrara MR, Ballin G, Zanchetta M, Giaquinto C, De Rossi A. Biological aging and immune senescence in children with perinatally acquired HIV. Journal of Immunology Research. 2020.
40. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
41. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
42. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
43. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
44. Igwe MC, Obeagu EI, Ogbuabor AO. Analysis of the Factors and Predictors of Adherence to Healthcare of People Living With Hiv/Aids In Tertiary Health Institutions In Enugu State. Madonna University Journal of Medicine and Health Sciences. 2022;2(3):42-57. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75.

Citation: Obeagu EI, Obeagu GU. Immunodeficiency and Immune Reconstitution in Pediatric HIV: Mechanisms, Challenges, and Therapeutic Strategies. Elite Journal of Immunology, 2024; 2(3): 62-79

45. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
46. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
47. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
48. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
49. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
50. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
51. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
52. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
53. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
54. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%

20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.

55. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
56. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
57. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
58. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
59. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
60. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
61. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
62. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
63. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
64. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
65. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
66. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.

Citation: Obeagu EI, Obeagu GU. Immunodeficiency and Immune Reconstitution in Pediatric HIV: Mechanisms, Challenges, and Therapeutic Strategies. Elite Journal of Immunology, 2024; 2(3): 62-79

67. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
68. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
69. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
70. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
71. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
72. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health. 2024;2(1):8-22.
73. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology. 2024;2(1):14-33.
74. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024;103(9): e37354.
75. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. Elite Journal of Immunology. 2024;2(1):1-3.
76. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology. 2024;2(1):34-46.
77. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
78. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine. 2024;2(1):35-46.
79. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com.;12(01).
80. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
81. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
82. Obeagu EI, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. Elite Journal of HIV. 2024;2(1):31-50.

Citation: Obeagu EI, Obeagu GU. Immunodeficiency and Immune Reconstitution in Pediatric HIV: Mechanisms, Challenges, and Therapeutic Strategies. Elite Journal of Immunology, 2024; 2(3): 62-79

83. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV. 2024;2(1):1-5.
84. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.
85. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Sciences. 2024;4(1):32-37.
86. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Sciences. 2024;4(1):38-44.
87. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science. 2024;2(1):33-42.
88. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
89. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine. 2024;2(2):104-15.
90. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology. 2024;2(1):47-64.
91. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.
92. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
93. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. Elite Journal of Public Health. 2024;2(1):22-34.
94. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.
95. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
96. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science. 2024;2(3):38-58.
97. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV. 2024;2(3):14-26.
98. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health. 2024;2(1):52-63.
99. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.

Citation: Obeagu EI, Obeagu GU. Immunodeficiency and Immune Reconstitution in Pediatric HIV: Mechanisms, Challenges, and Therapeutic Strategies. Elite Journal of Immunology, 2024; 2(3): 62-79

100. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review. 2024;2(1):37-50.
101. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
102. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science. 2024;2(3):59-72.
103. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science. 2024;2(2):5-15.
104. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine. 2024;2(1):35-46.
105. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.
106. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV. 2024;2(2):60-73.
107. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine. 2024;2(1):10-22.
108. Obeagu EI, AmaezeAA O, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science. 2024;2(2):33-46.
109. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.
110. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.
111. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology. 2024;2(3):33-44.
112. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. Elite Journal of Immunology. 2024;2(2):15-28.
113. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).
114. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
115. Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in Confronting HIV Stigma. Elite Journal of Public Health. 2024;2(3):22-36.

Citation: Obeagu EI, Obeagu GU. Immunodeficiency and Immune Reconstitution in Pediatric HIV: Mechanisms, Challenges, and Therapeutic Strategies. Elite Journal of Immunology, 2024; 2(3): 62-79

116. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV. 2024;2(1):16-30.
117. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology. 2024;2(1):47-64.
118. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2 (3).:10-24.
119. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024;2(1):33-45.
120. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV. 2024;2(1):51-64.
121. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51.
122. Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review. 2024;2(1):24-36.
123. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. Elite Journal of Immunology. 2024;2(3):1-8.
124. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV. 2024;2(1):1-5.
125. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2 (3).:42-57.
126. Obeagu EI, Obeagu GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review. 2024;2(1):1-6.
127. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
128. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Sciences. 2024;4(1):32-7.
129. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science. 2024;2(2):16-29.
130. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Sciences. 2024;4(1):38-44.
131. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science. 2024;2(2):1-7.
132. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.

Citation: Obeagu EI, Obeagu GU. Immunodeficiency and Immune Reconstitution in Pediatric HIV: Mechanisms, Challenges, and Therapeutic Strategies. Elite Journal of Immunology, 2024; 2(3): 62-79

133. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):9-19.
134. Obeagu EI, Obeagu GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review. 2024;2(1):42-60.
135. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine. 2024;2(2):104-5.
136. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2 (3).:25-41.
137. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science. 2024;2(1):33-42.
138. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV. 2024;2(2):43-59.
139. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science. 2024;2(3):23-35.
140. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.
141. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(3):84-99.
142. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science. 2024;2(2):20-35.
143. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. Elite Journal of Laboratory Medicine. 2024;2(2):30-46.
144. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
145. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health. 2024;2(1):35-51.
146. Kalu OA, Ukibe NR, Onyenekwe CC, Okoyeagu RC, Nnaemeka WS, Onyenekwe AJ, Ukibe EG, Ukibe BC, Ukibe VE, Obeagu EI. Assessment of Serum Cystatin C, Microalbumin Levels and Egfr in HIV Seropositive Individuals based on Age and Gender in NAUTH, Nnewi, Nigeria. Elite Journal of Medicine. 2024;2(3):48-59.

Citation: Obeagu EI, Obeagu GU. Immunodeficiency and Immune Reconstitution in Pediatric HIV: Mechanisms, Challenges, and Therapeutic Strategies. Elite Journal of Immunology, 2024; 2(3): 62-79

147. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology. 2024;2(2):43-59.
148. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):14-32.
149. Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review. 2024;2(1):17-41.
150. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. Elite Journal of Medicine. 2024;2(1):1-6.
151. Obeagu EI, GU EE. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2 (3).:111-7.
152. Lu J, Wu W. Cholinergic modulation of the immune system–A novel therapeutic target for myocardial inflammation. International Immunopharmacology. 2021; 93:107391.
153. Ford D, Turner R, Turkova A, Penazzato M, Musiime V, Bwakura-Dangarembizi M, Violari A, Chabala C, Puthanakit T, Sudjaritruk T, Cressey TR. Optimizing clinical trial design to maximize evidence generation in pediatric HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2018;78: S40-48.
154. Obeagu EI, Obeagu GU. Anemia in HIV: The Role of Erythropoietin in Disease Progression. *Elite Journal of Haematology*, *2024; 2(4):* 51-67
155. Obeagu EI, Obeagu GU. ART and Platelet Dynamics: Assessing Implications for HIV Patient Care**.** *Elite Journal of Haematology*, *2024; 2(4):* 68-85
156. Obeagu EI, Obeagu GU. Impact of Breastfeeding on Infant Immune Responses in the Context of HIV**.** Elite Journal of Nursing and Health Science, 2024; 2(4):23-39
157. Obeagu EI, Obeagu GU. HIV-Induced Immune Exhaustion in Neonates: A Review of Mechanisms and Implications. Elite Journal of Immunology, 2024; 2(3): 45-61

Citation: Obeagu EI, Obeagu GU. Immunodeficiency and Immune Reconstitution in Pediatric HIV: Mechanisms, Challenges, and Therapeutic Strategies. Elite Journal of Immunology, 2024; 2(3): 62-79